ADCT — ADC Therapeutics SA Cashflow Statement
0.000.00%
- $131.91m
- $314.77m
- $70.84m
- 20
- 31
- 28
- 15
Annual cashflow statement for ADC Therapeutics SA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 10-K | 10-K | 10-K |
Standards: | IFRS | IFRS | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -246 | -230 | -157 | -240 | -158 |
Depreciation | |||||
Amortisation | |||||
Deferred Taxes | |||||
Non-Cash Items | 63.8 | 46.5 | 64.6 | 35.1 | 25.4 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 11.6 | -26.4 | -46.6 | 45.9 | 5.34 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -169 | -233 | -138 | -119 | -124 |
Capital Expenditures | -2.81 | -6.38 | -0.687 | -3.22 | -0.867 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -0.019 | -0.297 | — | — | — |
Other Investing Cash Flow | |||||
Cash from Investing Activities | -2.83 | -6.67 | -0.687 | -3.22 | -0.867 |
Financing Cash Flow Items | — | — | -1.31 | — | -1.16 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 495 | 267 | -0.897 | 73.9 | 97.1 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 324 | 27.3 | -140 | -47.8 | -27.7 |